18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
May 2023 in “Authorea (Authorea)” Levofloxacin may cause skin discoloration and hair loss as side effects.
11 citations
,
June 2023 in “Drug Delivery and Translational Research” The gel with apocynin-loaded nanoparticles shows promise for treating rheumatoid arthritis.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
1 citations
,
December 2025 in “Journal of the American Academy of Dermatology” 5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
June 2024 in “BioSCIENCE” Microinfusion of methotrexate can help treat frontal fibrosing alopecia.
3 citations
,
October 2011 in “JAT. Journal of applied toxicology/Journal of applied toxicology” Doxazosin mesylate and saw palmetto cause genetic changes in fruit flies.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
1 citations
,
October 2010 in “Faṣlnāmah-i bīmārīhā-yi pūst” Methotrexate with corticosteroids can help regrow hair in severe alopecia areata but may cause relapses and side effects.
The document's conclusion cannot be provided because the document is not available or cannot be read.
July 2024 in “Journal of Investigative Dermatology” 5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
4 citations
,
September 2018 in “The Journal of Dermatology” A man's hair regrew from alopecia areata after using tofacitinib and experiencing contact dermatitis from a wig device.
August 2022 in “Dermatology Online Journal” Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
32 citations
,
September 2010 in “Stress” Neurosteroids help protect fetal brains from asphyxia damage.
July 2025 in “Veterinary Parasitology Regional Studies and Reports” NexGard® and Frontline Combo® are both 100% effective at eliminating lice in dogs.
January 2014 in “Side effects of drugs annual” Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.
20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
14 citations
,
October 2003 in “Annals of Oncology” About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
6 citations
,
November 2023 in “Clinical Pharmacokinetics” Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
December 2025 in “PubMed” The minoxidil and finasteride foam remains stable and effective for 180 days at room temperature.
June 2019 in “Reactions Weekly”
6 citations
,
November 2007 in “British Journal of Dermatology” Fulvestrant solution doesn't help hair loss in men and postmenopausal women.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
January 2026 in “GSC Biological and Pharmaceutical Sciences” Adapalene, Diosmin, and Azelastine could be repurposed to treat onchocerciasis.